Quinazoline derivatives as metabolically inert antifolate compounds.

Details for Australian Patent Application No. 2005282241 (hide)

Owner Chelsea Therapeutics, Inc.

Inventors Pedder, Simon; Roberts, Michael J.

Agent Spruson & Ferguson

Pub. Number AU-B-2005282241

PCT Pub. Number WO2006/029385

Priority 60/607,883 08.09.04 US; 60/611,482 20.09.04 US

Filing date 8 September 2005

Wipo publication date 16 March 2006

Acceptance publication date 3 March 2011

International Classifications

C07D 239/95 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/029385 Priority application(s): WO2006/029385

3 March 2011 Application Accepted

  Published as AU-B-2005282241

30 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005282249-Process for preparation of mixtures of polypeptides using purified hydrobromic acid

2005282236-Controlled release delivery system for bio-active agents